Evidence map›Paper›PMID 39024018›Full record

ArticleJMIR research protocols2024

Quantification of Urinary Exosomal Prostate-Specific Antigen for the Diagnosis of Prostate Cancer Using Clinical Laboratory-Based Techniques: Protocol for a Case-Control Study.

Guorong Li, Yannick Tholance, Nora Mallouk, Louis Waeckel, Pascale Flandrin, Bruno Bali, Lionel Badet, Pierre Cornillon

Abstract read
In one paragraph

Article in JMIR research protocols, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Guorong LiDepartment of Urology, North Hospital, CHU Saint-Etienne, Saint-Etienne, France.ORCID 0000-0003-4457-3380
Yannick TholanceLaboratory of Biochemistry, North Hospital, CHU Saint-Etienne, Saint-Etienne, France.ORCID 0000-0002-1826-3031
Nora MalloukCenter of Electronic Microscopy, CMES, Faculty of Medicine, University of Jean Monnet, Saint-Etienne, France.ORCID 0000-0002-6691-0977
Louis WaeckelDepartment of Urology, North Hospital, CHU Saint-Etienne, Saint-Etienne, France.ORCID 0000-0002-4941-2415
Pascale FlandrinLaboratory of Molecular Biology, North Hospital, CHU Saint-Etienne, Saint-Etienne, France.ORCID 0000-0001-6258-7028
Bruno BaliDepartment of Urology, North Hospital, CHU Saint-Etienne, Saint-Etienne, France.ORCID 0009-0009-1809-7959
Lionel Badet *Department of Urology, North Hospital, CHU Saint-Etienne, Saint-Etienne, France.ORCID 0000-0002-9596-0279
Pierre Cornillon *Department of Medical Oncology, North Hospital, CHU Saint-Etienne, Saint-Etienne, France.ORCID 0000-0002-9275-1762

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProstate cancer is the most common cancer in men and represents a major public health problem. The current method for the diagnosis or screening of prostate cancer is invasive and costly. There have been renewed and innovative studies searching for urinary biomarkers to aid in the diagnosis of prostate cancer, especially with technologies based on urinary exosomes. However, technologies based on urine exosomes usually need expensive machines such as an ultracentrifuge and they are difficult to standardize, which hinder their application in clinical laboratories. We have optimized and standardized the isolation of urinary exosomes with the precipitation method. We have found that urinary exosomal prostate-specific antigen (PSA) can be quantified by automatic Elecsys total PSA technique.

objectiveIn this study, our objective is to utilize urinary exosomes from prostate cancer for the development of a test to aid in its diagnosis.

methodsExosomes from the prostate cancer cell line LNCaP was used to set up the technique. To analyze urine samples from patients, the methods include the collection of first-void urine using the Colli-Pee device, the isolation of urine exosomes using the optimized precipitation method, and the quantification of exosomal PSA by Elecsys total PSA.

resultsThis will be a 2-year study. We will start including patients and controls in the last quarter of 2024. We expect the results to be published in the second quarter of 2027.

conclusionsThis is the first study to quantify urinary exosomal PSA using the Elecsys total PSA technique for the diagnosis of prostate cancer. This study emphasizes techniques that are suitable for implementation in clinical laboratories, which will facilitate the application of urinary exosomes to simplify and improve the diagnosis and screening of prostate cancer. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/63551.

Indexed as

ExosomesProstate-Specific AntigenProstatic NeoplasmsBiomarkers, TumorCase-Control StudiesHumansMaleBiomarkers, TumorProstate-Specific Antigendiagnosisliquid biopsyprostate cancerprostate-specific antigenPSAurinary exosome

Identifiers

PMID39024018
PMCPMC11425016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.